Key result
Ximelagatran b.i.d. reduced total venous thromboembolism compared to warfarin, but increased ALT elevation during follow-up.
Why the study?
Does ximelagatran reduce total venous thromboembolism compared to warfarin in patients undergoing major orthopedic knee surgery?
Systematic Review (n=4,914)
Does ximelagatran reduce total venous thromboembolism compared to warfarin in patients undergoing major orthopedic knee surgery?
Ximelagatran 36 mg twice daily is more effective than warfarin for VTE prophylaxis after major orthopedic knee surgery, but carries a higher risk of delayed ALT elevation.
Answers are grounded in this paper and cite their sources.
Ximelagatran reduces VTE versus warfarin after knee surgery; extends meta-analytic support but requires ALT monitoring for hepatotoxicity risk.
BACKGROUND: Ximelagatran has been recently studied for prophylaxis in surgical orthopedic cases. PURPOSE: We proposed to establish whether interventions involving ximelagatran, as compared with warfarin, would increase thromboembolic prophylaxis in patients undergoing major orthopedic knee surgery. DATA SOURCE: Studies with random assignment were identified by an electronic search of the medical literature up to 2006. Data were double-entered into the Review Manager software, version 4.2.5. DATA SYNTHESIS: We included three well-conducted clinical trials involving 4,914 participants. Sub-groups with two dosages of ximelagatran (24 mg and 36 mg, b.i.d.), were defined. Ximelagatran showed significantly lower frequency of total venous thromboembolism (VTE) than warfarin, but only with the 36-mg dosage (risk relative, RR: 0.72; 95% confidence interval, CI: 0.64-0.81; p < 0.00001). For the 24-mg subgroup, total VTE frequency was similar (RR: 0.86; 95% CI: 0.73-1.01; p = 0.06). No significant differences were shown with either ximelagatran dosage for deep vein thrombosis (DVT), pulmonary embolism, any bleeding or severe bleeding. At the end of the treatment, alanine aminotransferase (ALT) elevation was less frequent in the 24-mg ximelagatran sub-group (RR: 0.33; 95% CI: 0.12-0.91; p = 0.03], but during the follow-up period, the ALT elevation rate was greater in the 36-mg ximelagatran group (RR: 6.97; 95% CI: 1.26-38.50; p = 0.03]. CONCLUSIONS: Ximelagatran appears to be more effective than warfarin when used in higher dosages (36 mg b.i.d.), but at the expense of increased frequency of ALT elevation during the follow-up period.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2006) conducted a systematic review in Major orthopedic knee surgery (n=4,914). Ximelagatran vs. Warfarin was evaluated on Total venous thromboembolism (VTE) (RR 0.72, 95% CI 0.64-0.81, p=<0.00001). Ximelagatran b.i.d. reduced total venous thromboembolism compared to warfarin, but increased ALT elevation during follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: